Clinverse, Inc. Announces Strategic Partnership with eClinical Insights
Clinverse, Inc. and eClinical Insights announced today they have formed a strategic partnership.
Clinverse’s
“Together, we are able to offer CROs and clinical trial sponsors a best-of-breed, fully integrated solution that delivers real-time visibility across the eClinical ecosystem,” said Denis Connaghan, CEO of Clinverse. “Joint customers stand to gain a measureable return on investment, increased competitive advantage, and decreased ramp-up time and learning curve.”
Using the ClinPay application programming interface (API) and eClinical Insights proprietary integration framework, the integrated solution offers seamless data integration with any other clinical technology. With the financial lifecycle management of ClinPay and the combined trial management capabilities of eClinical Insights' TrialOps Director™ and inTrial Metrix™ applications, sponsors and CROs can further improve the performance of their clinical trials while substantially reducing labor costs associated with payment and accounting processes for clinical vendors and investigative sites.
“Adding Clinverse as a strategic partner in our integrated technology network enables us to expand the reach and capabilities of our platform,” said Peg Regan, President & CEO of eClinical Insights. “This partnership and integrated solution fit seamlessly with our philosophy and approach to improving trial performance across a complex eClinical ecosystem.”
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025